Published in Mol Cancer Ther on September 01, 2008
NF-kappaB and cancer: how intimate is this relationship. Mol Cell Biochem (2009) 2.03
Apoptosis by dietary agents for prevention and treatment of prostate cancer. Endocr Relat Cancer (2010) 1.26
Cancer biomarker discovery: the entropic hallmark. PLoS One (2010) 1.26
Oral infusion of pomegranate fruit extract inhibits prostate carcinogenesis in the TRAMP model. Carcinogenesis (2011) 1.03
Pomegranate extract induces apoptosis in human prostate cancer cells by modulation of the IGF-IGFBP axis. Growth Horm IGF Res (2009) 1.00
Pomegranate-mediated chemoprevention of experimental hepatocarcinogenesis involves Nrf2-regulated antioxidant mechanisms. Carcinogenesis (2011) 0.97
Potent health effects of pomegranate. Adv Biomed Res (2014) 0.95
A Comprehensive Review of Punica granatum (Pomegranate) Properties in Toxicological, Pharmacological, Cellular and Molecular Biology Researches. Iran J Pharm Res (2012) 0.95
A double-blind, placebo-controlled randomised trial evaluating the effect of a polyphenol-rich whole food supplement on PSA progression in men with prostate cancer--the U.K. NCRN Pomi-T study. Prostate Cancer Prostatic Dis (2014) 0.93
Specific pomegranate juice components as potential inhibitors of prostate cancer metastasis. Transl Oncol (2012) 0.91
A double-blind, randomized, neoadjuvant study of the tissue effects of POMx pills in men with prostate cancer before radical prostatectomy. Cancer Prev Res (Phila) (2013) 0.86
In vitro antiproliferativeactivity of Annona reticulata roots on human cancer cell lines. Pharmacognosy Res (2011) 0.85
Complementary and alternative medicines in prostate cancer: from bench to bedside? Oncologist (2012) 0.85
Suppression of urinary bladder urothelial carcinoma cell by the ethanol extract of pomegranate fruit through cell cycle arrest and apoptosis. BMC Complement Altern Med (2013) 0.84
Ethanol extract of Remotiflori radix induces endoplasmic reticulum stress-mediated cell death through AMPK/mTOR signaling in human prostate cancer cells. Sci Rep (2015) 0.83
Potential Effects of Pomegranate Polyphenols in Cancer Prevention and Therapy. Oxid Med Cell Longev (2015) 0.83
Efficacy and safety of pomegranate medicinal products for cancer. Evid Based Complement Alternat Med (2015) 0.81
Pomegranate Juice Metabolites, Ellagic Acid and Urolithin A, Synergistically Inhibit Androgen-Independent Prostate Cancer Cell Growth via Distinct Effects on Cell Cycle Control and Apoptosis. Evid Based Complement Alternat Med (2013) 0.81
Pomegranate and its components as alternative treatment for prostate cancer. Int J Mol Sci (2014) 0.81
Ellagic Acid Inhibits Bladder Cancer Invasiveness and In Vivo Tumor Growth. Nutrients (2016) 0.80
Bridging cross-cultural gaps: monitoring herbal use during chemotherapy in patients referred to integrative medicine consultation in Israel. Support Care Cancer (2014) 0.79
Pomegranate extracts and cancer prevention: molecular and cellular activities. Anticancer Agents Med Chem (2013) 0.79
Pomegranate Extracts in the Management of Men's Urologic Health: Scientific Rationale and Preclinical and Clinical Data. Evid Based Complement Alternat Med (2013) 0.78
The Effect of Commiphora molmol (Myrrh) in Treatment of Trichomoniasis vaginalis infection. Iran Red Crescent Med J (2011) 0.78
A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer. Prostate Cancer Prostatic Dis (2015) 0.78
Food-based natural products for cancer management: Is the whole greater than the sum of the parts? Semin Cancer Biol (2016) 0.75
Clarification of the molecular pathway of Taiwan local pomegranate fruit juice underlying the inhibition of urinary bladder urothelial carcinoma cell by proteomics strategy. BMC Complement Altern Med (2016) 0.75
Bioactive natural products for chemoprevention and treatment of castration-resistant prostate cancer. Semin Cancer Biol (2016) 0.75
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM). Nutrients (2016) 0.75
Potential Antitumor Effects of Pomegranates and Its Ingredients. Pharmacogn Rev (2017) 0.75
A review of pomegranate in prostate cancer. Prostate Cancer Prostatic Dis (2017) 0.75
Pomegranate for Prevention and Treatment of Cancer: An Update. Molecules (2017) 0.75
Molecular determinants of resistance to antiandrogen therapy. Nat Med (2003) 18.90
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
NF-kappaB in cancer: from innocent bystander to major culprit. Nat Rev Cancer (2002) 11.39
Aberrant rel/nfkb genes and activity in human cancer. Oncogene (1999) 5.62
Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol (1999) 4.85
Molecular targets of dietary agents for prevention and therapy of cancer. Biochem Pharmacol (2006) 4.69
Series introduction: the transcription factor NF-kappaB and human disease. J Clin Invest (2001) 4.18
Progression of metastatic human prostate cancer to androgen independence in immunodeficient SCID mice. Nat Med (1997) 3.46
Blockade of NF-kappaB activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis. Oncogene (2001) 2.71
The role of IKK in constitutive activation of NF-kappaB transcription factor in prostate carcinoma cells. J Cell Sci (2002) 1.90
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
Mechanisms of constitutive NF-kappaB activation in human prostate cancer cells. Prostate (2002) 1.86
Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. J Agric Food Chem (2007) 1.74
Inhibition of NF-kappaB, clonogenicity, and radiosensitivity of human cancer cells. J Natl Cancer Inst (1999) 1.69
Constitutive activation of IkappaB kinase alpha and NF-kappaB in prostate cancer cells is inhibited by ibuprofen. Oncogene (1999) 1.62
Nuclear factor-kappaB/p65 (Rel A) is constitutively activated in human prostate adenocarcinoma and correlates with disease progression. Neoplasia (2004) 1.56
NF-kappa B activates prostate-specific antigen expression and is upregulated in androgen-independent prostate cancer. Mol Cell Biol (2002) 1.55
Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr (2006) 1.51
Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model. Prostate (2005) 1.48
Retracted Tumor necrosis factor-alpha-induced apoptosis in prostate cancer cells through inhibition of nuclear factor-kappaB by an IkappaBalpha "super-repressor". Clin Cancer Res (2000) 1.46
Patterns of inflammation in prostatic hyperplasia: a histologic and bacteriologic study. J Urol (1979) 1.44
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem (2007) 1.41
Nuclear factor-kappaB nuclear localization is predictive of biochemical recurrence in patients with positive margin prostate cancer. Clin Cancer Res (2004) 1.40
NF-kappaB is constitutively activated in high-grade squamous intraepithelial lesions and squamous cell carcinomas of the human uterine cervix. Oncogene (2003) 1.35
NFkappaB: a pivotal transcription factor in prostate cancer metastasis to bone. Clin Orthop Relat Res (2003) 1.30
Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer (2005) 1.26
Pomegranate fruit extract modulates UV-B-mediated phosphorylation of mitogen-activated protein kinases and activation of nuclear factor kappa B in normal human epidermal keratinocytes paragraph sign. Photochem Photobiol (2005) 1.19
A novel mechanism for the inhibition of NF-kappaB activation in vascular endothelial cells by natural antioxidants. FASEB J (2002) 1.15
Ellagitannin-rich pomegranate extract inhibits angiogenesis in prostate cancer in vitro and in vivo. Int J Oncol (2008) 1.09
Effect of isocaloric low-fat diet on prostate cancer xenograft progression to androgen independence. Cancer Res (2004) 1.03
Epidermal growth factor receptor inhibition sensitizes renal cell carcinoma cells to the cytotoxic effects of bortezomib. Mol Cancer Ther (2007) 1.02
CL1-GFP: an androgen independent metastatic tumor model for prostate cancer. J Urol (2000) 0.93
The role of constitutive NF-kappaB activity in PC-3 human prostate cancer cell invasive behavior. Clin Exp Metastasis (2000) 0.92
On the cytotoxicity of some microbial volatile organic compounds as studied in the human lung cell line A549. Chemosphere (2002) 0.90
Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med (2012) 24.06
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 12.44
Guideline for management of the clinical T1 renal mass. J Urol (2009) 8.26
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 6.51
Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res (2004) 4.69
Impact of obesity on biochemical control after radical prostatectomy for clinically localized prostate cancer: a report by the Shared Equal Access Regional Cancer Hospital database study group. J Clin Oncol (2003) 3.62
Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst (2003) 3.44
Obesity-related plasma hemodilution and PSA concentration among men with prostate cancer. JAMA (2007) 3.25
The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer. Contemp Clin Trials (2008) 3.25
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial. JAMA (2006) 2.97
Aire deficient mice develop multiple features of APECED phenotype and show altered immune response. Hum Mol Genet (2002) 2.91
In vitro antiproliferative, apoptotic and antioxidant activities of punicalagin, ellagic acid and a total pomegranate tannin extract are enhanced in combination with other polyphenols as found in pomegranate juice. J Nutr Biochem (2005) 2.71
Prostate size and risk of high-grade, advanced prostate cancer and biochemical progression after radical prostatectomy: a search database study. J Clin Oncol (2005) 2.57
Outcomes after radical prostatectomy among men who are candidates for active surveillance: results from the SEARCH database. Urology (2010) 2.45
Prognostic relevance of the mTOR pathway in renal cell carcinoma: implications for molecular patient selection for targeted therapy. Cancer (2007) 2.38
Prostate cancer severity among low income, uninsured men. J Urol (2008) 2.38
Hybrid renal cell carcinomas containing histopathologic features of chromophobe renal cell carcinomas and oncocytomas have excellent oncologic outcomes. Eur Urol (2009) 2.37
Obesity, serum prostate specific antigen and prostate size: implications for prostate cancer detection. J Urol (2006) 2.31
Natural history of persistently elevated prostate specific antigen after radical prostatectomy: results from the SEARCH database. J Urol (2009) 2.23
Freedom from a detectable ultrasensitive prostate-specific antigen at two years after radical prostatectomy predicts a favorable clinical outcome: analysis of the SEARCH database. Urology (2009) 2.23
Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling. J Urol (2011) 2.21
Health ramifications of the obesity epidemic. Surg Clin North Am (2005) 2.10
Multiinstitutional validation of the UCSF cancer of the prostate risk assessment for prediction of recurrence after radical prostatectomy. Cancer (2006) 1.97
Race, biochemical disease recurrence, and prostate-specific antigen doubling time after radical prostatectomy: results from the SEARCH database. Cancer (2007) 1.96
Color Doppler sonography reliably identifies testicular torsion in boys. Urology (2009) 1.95
Growth inhibitory effect of low fat diet on prostate cancer cells: results of a prospective, randomized dietary intervention trial in men with prostate cancer. J Urol (2010) 1.94
Comparison of antioxidant potency of commonly consumed polyphenol-rich beverages in the United States. J Agric Food Chem (2008) 1.92
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer. Clin Cancer Res (2006) 1.86
Defining the ideal cutpoint for determining PSA recurrence after radical prostatectomy. Prostate-specific antigen. Urology (2003) 1.84
Blackberry, black raspberry, blueberry, cranberry, red raspberry, and strawberry extracts inhibit growth and stimulate apoptosis of human cancer cells in vitro. J Agric Food Chem (2006) 1.84
Intensive lifestyle changes may affect the progression of prostate cancer. J Urol (2005) 1.81
Race as an outcome predictor after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. Urology (2002) 1.81
Male gender is a predictor of morbidity and age a predictor of mortality for patients undergoing gastric bypass surgery. Ann Surg (2002) 1.80
Fluorescence cystoscopy with high-resolution optical coherence tomography imaging as an adjunct reduces false-positive findings in the diagnosis of urothelial carcinoma of the bladder. Eur Urol (2009) 1.79
Limitations of MTT and MTS-based assays for measurement of antiproliferative activity of green tea polyphenols. PLoS One (2010) 1.77
Delayed radical prostatectomy for intermediate-risk prostate cancer is associated with biochemical recurrence: possible implications for active surveillance from the SEARCH database. Prostate (2012) 1.76
Growth inhibition of human tumor cell lines by withanolides from Withania somnifera leaves. Life Sci (2003) 1.76
Cytoreductive nephrectomy for kidney cancer with sarcomatoid histology--is up-front resection indicated and, if not, is it avoidable? J Urol (2009) 1.75
Ganoderma lucidum causes apoptosis in leukemia, lymphoma and multiple myeloma cells. Leuk Res (2006) 1.74
Safety and antioxidant activity of a pomegranate ellagitannin-enriched polyphenol dietary supplement in overweight individuals with increased waist size. J Agric Food Chem (2007) 1.74
Characterization of human fibrocytes as circulating adipocyte progenitors and the formation of human adipose tissue in SCID mice. FASEB J (2005) 1.68
Upgrading and downgrading of prostate needle biopsy specimens: risk factors and clinical implications. Urology (2007) 1.67
Smoking negatively impacts renal cell carcinoma overall and cancer-specific survival. Cancer (2011) 1.64
Prognostic value of microvascular invasion in predicting the cancer specific survival and risk of metastatic disease in renal cell carcinoma: a multicenter investigation. J Urol (2011) 1.63
Histologic evaluation of metastases in renal cell carcinoma with sarcomatoid transformation and its implications for systemic therapy. Cancer (2010) 1.61
Isolation and identification of strawberry phenolics with antioxidant and human cancer cell antiproliferative properties. J Agric Food Chem (2008) 1.61
A molecular classification of papillary renal cell carcinoma. Cancer Res (2005) 1.60
Circulating fatty acids and prostate cancer risk in a nested case-control study: the Multiethnic Cohort. Cancer Causes Control (2008) 1.60
Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta (2004) 1.60
Statin medication use and the risk of biochemical recurrence after radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) Database. Cancer (2010) 1.59
Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer (2008) 1.58
Postoperative statin use and risk of biochemical recurrence following radical prostatectomy: results from the Shared Equal Access Regional Cancer Hospital (SEARCH) database. BJU Int (2014) 1.58
Protective effects of plasma carotenoids on the risk of bladder cancer. J Urol (2006) 1.56
CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis. J Urol (2009) 1.54
Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer (2008) 1.53
Clinical outcome of patients with docetaxel-resistant hormone-refractory prostate cancer treated with second-line cyclophosphamide-based metronomic chemotherapy. Med Oncol (2009) 1.52
Total cranberry extract versus its phytochemical constituents: antiproliferative and synergistic effects against human tumor cell lines. J Agric Food Chem (2004) 1.52
Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr (2006) 1.51
The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer. Cancer (2014) 1.51
Carbohydrate restriction, prostate cancer growth, and the insulin-like growth factor axis. Prostate (2008) 1.50
Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res (2006) 1.50
Improved clinical staging system combining biopsy laterality and TNM stage for men with T1c and T2 prostate cancer: results from the SEARCH database. J Urol (2003) 1.49
Pomegranate juice, total pomegranate ellagitannins, and punicalagin suppress inflammatory cell signaling in colon cancer cells. J Agric Food Chem (2006) 1.49
Green tea inhibits vascular endothelial growth factor (VEGF) induction in human breast cancer cells. J Nutr (2002) 1.48
Antioxidant-rich spice added to hamburger meat during cooking results in reduced meat, plasma, and urine malondialdehyde concentrations. Am J Clin Nutr (2010) 1.48
PC-SPES: herbal formulation for prostate cancer. Urology (2002) 1.48
Tart cherry anthocyanins inhibit tumor development in Apc(Min) mice and reduce proliferation of human colon cancer cells. Cancer Lett (2003) 1.48
Randomized clinical trial of brewed green and black tea in men with prostate cancer prior to prostatectomy. Prostate (2014) 1.47
Bioavailability and antioxidant activity of tea flavanols after consumption of green tea, black tea, or a green tea extract supplement. Am J Clin Nutr (2004) 1.46
Sex, age, and surgeon decision on nephron-sparing surgery are independent predictors of renal masses with benign histologic findings--a multicenter survey. Urology (2010) 1.46
Prospective randomized multicenter study comparing prostate cancer detection rates of end-fire and side-fire transrectal ultrasound probe configuration. Urology (2012) 1.46
Effect of saw palmetto soft gel capsule on lower urinary tract symptoms associated with benign prostatic hyperplasia: a randomized trial in Shanghai, China. J Urol (2007) 1.44
The role of CXCR2/CXCR2 ligand biological axis in renal cell carcinoma. J Immunol (2005) 1.44
Low CAIX expression and absence of VHL gene mutation are associated with tumor aggressiveness and poor survival of clear cell renal cell carcinoma. Int J Cancer (2008) 1.43
Low-fat high-fiber diet decreased serum and urine androgens in men. J Clin Endocrinol Metab (2005) 1.42
Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem (2007) 1.41